Sativex® commercialisation approval in Italy
Sativex® commercialisation approval in Italy
GW Pharmaceuticals plc has announced that it has received commercialisation approval for its prescription medicine Sativex® in Italy. A full marketing authorization has been granted by the authorities in Italy for the treatment of moderate to severe spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other anti-spasticity medications....... Read More - http://www.ms-uk.org/index.cfm/sativex
MS-UK - http://www.ms-uk.org/